Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?

Cholesteryl ester transfer protein (CETP) inhibitors significantly increase serum high-density lipoprotein cholesterol (HDL) cholesterol levels and decrease low-density lipoprotein cholesterol (LDL) cholesterol concentration. However, three drugs of this class failed to show a decrease of cardiovasc...

Descripción completa

Detalles Bibliográficos
Autores principales: Filippatos, Theodosios D., Kei, Anastazia, Elisaf, Moses S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5750532/
https://www.ncbi.nlm.nih.gov/pubmed/28961179
http://dx.doi.org/10.3390/diseases5040021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5750532/
https://www.ncbi.nlm.nih.gov/pubmed/28961179
http://dx.doi.org/10.3390/diseases5040021

Ejemplares similares